在链激酶或重组体组织型纤溶酶原激活剂(rt-PA)治疗成功的急性心肌梗塞患者中,2周内梗塞区供血冠脉再次阻塞的发生率为5～45%;复发性心绞痛发生率≤50%。临床或血管造影资料都不能预测再次阻塞的危险。作者复习文献后发现,在胸痛症状开始 In streptokinase or recombinant tissue plasminogen activator (rt-PA) treatment of patients with acute myocardial infarction, coronary artery occlusion within 2 weeks the incidence of re-occlusion was 5 to 45%; recurrent angina The incidence of ≤ 50%. Neither clinical nor angiographic data predict the risk of reocclusion. The authors review the literature and found that the onset of chest pain